Phase 3 Clinical Trial Data

Hospitals

DrueNovember 29, 2018
1,052

Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More »
Biologics

Josh SandbergNovember 1, 2018
1,137

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More »